Myriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium
November 17 2015 - 6:05AM
New Data on the myChoice® HRD
and myRisk™ Hereditary Cancer Tests Will be
Highlighted
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, announced today that it will
present eight posters at the 2015 San Antonio Breast Cancer
Symposium (SABCS) being held Dec. 8 to 12, 2015 in San Antonio,
Texas.
"Myriad is committed to bringing transformative molecular
diagnostics to people with cancer. Our data at SABCS showcase our
expanding portfolio of companion diagnostics and their potential to
help personalize treatments for people with breast cancer," said
Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad
Genetic Laboratories. "We're also excited about several new studies
that highlight the ability of our myRisk Hereditary Cancer test to
identify patients at risk for hereditary cancers."
A list of the Myriad presentations at SABCS is below. Follow
Myriad on Twitter via @MyriadGenetics and stay informed about
symposium news and updates by using the hashtag #SABCS15.
myChoice HRD Poster Presentations
- Title: The role of germline BRCA status and
Homologous Recombination Deficiency and response to neoadjuvant
weekly paclitaxel followed by anthracycline-based chemotherapy.
Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m.
CT. Location: Poster P3-07-29.
- Title: Homologous recombination deficiency
(HRD) as a predictive biomarker of response to preoperative
systemic therapy (PST) in TBCRC008 comprising a platinum in
HER2-negative primary operable breast cancer.
Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m.
CT. Location: Poster P3-07-13.
- Title: Homologous recombination deficiency
(HRD) as a predictive biomarker of response to neoadjuvant
platinum-based therapy in patients with triple negative breast
cancer (TNBC); A pooled analysis. Date: Thursday,
Dec. 10, 2015: 5:00 to 7:00 p.m. CT. Location:
Poster P3-07-12.
myRisk Hereditary Cancer Poster
Presentations
- Title: Predisposing germline mutations in an
unselected academic breast cancer (BC) cohort.
Date: Wednesday, Dec. 9, 2015: 5:00 to 7:00 p.m.
CT. Location: Poster P1-08-07.
- Title: The patient experience in a prospective
trial of multiple-gene panel testing for cancer risk.
Date: Thursday, Dec. 10, 2015: 7:30 to 9:00 a.m.
CT. Location: Poster P2-09-07.
- Title: Interim analysis of multiplex gene
panel testing for inherited susceptibility to breast cancer.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-01.
- Title: Multiplex Identification of genetic
etiologies among women with bilateral breast cancer using a 25-gene
hereditary cancer panel. Date: Friday, Dec. 11,
2015: 5:00 to 7:00 p.m. CT. Location: Poster
Discussion PD7-02.
- Title: Characterization of Li-Fraumeni
syndrome diagnosed using a 25-gene hereditary cancer panel.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-03.
For more information about these presentations, please visit the
SABCS website at https://www.sabcs.org/.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related the Company's commitment to
bringing transformative molecular diagnostics to people with
cancer; our expanding portfolio of companion diagnostics and their
potential to help personalize treatments for people with breast
cancer; the ability of our myRisk Hereditary Cancer test to
identify patients at risk for hereditary cancers; and the Company's
strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers'
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
CONTACT: Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024